Colchicine demonstrated clinical benefits in the treatment of stable coronary artery disease. Our aim was to evaluate the effects of colchicine on atherosclerotic plaque stabilization. Atherosclerosis was induced in the abdominal aorta of 20 rabbits with high-cholesterol diet and balloon endothelial denudation. Rabbits were randomized to receive either colchicine or placebo. All animals underwent MRI, 18F-FDG PET/CT, optical coherence tomography (OCT), and histology. Similar progression of atherosclerotic burden was observed in the two groups as relative increase of normalized wall index (NWI). Maximum 18F-FDG standardized uptake value (meanSUVmax) decreased after colchicine treatment, while it increased in the placebo group with a trend toward significance. Animals with higher levels of cholesterol showed significant differences in favor to colchicine group, both as NWI at the end of the protocol and as relative increase in meanSUVmax. Colchicine may stabilize atherosclerotic plaque by reducing inflammatory activity and plaque burden, without altering macrophage infiltration or plaque typology.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
- 18F-FDG PET/CT:
18F-Fluorodeoxyglucose integrated with computed tomography
Magnetic resonance imaging
Normalized wall index
Optical coherence tomography
Standardized uptake values
Tousoulis, D., et al. (2016). Inflammatory cytokines in atherosclerosis: current therapeutic approaches. European Heart Journal, 37(22), 1723–1732.
Libby, P. (2012). Inflammation in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 32(9), 2045–2051.
Naruko, T., et al. (2002). Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation, 106(23), 2894–2900.
Vacek, T. P., et al. (2015). Matrix metalloproteinases in atherosclerosis: role of nitric oxide, hydrogen sulfide, homocysteine, and polymorphisms. Vascular Health and Risk Management, 11, 173–183.
Peters, M. J., et al. (2009). Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis and Rheumatism, 61(11), 1571–1579.
Ridker, P. M. (2014). Inflammation, C-reactive protein, and cardiovascular disease: moving past the marker versus mediator debate. Circulation Research, 114(4), 594–595.
Moreno, P. R., & Kini, A. (2012). Resolution of inflammation, statins, and plaque regression. JACC: Cardiovascular Imaging, 5(2), 178–181.
Ridker, P. M., et al. (2017). Antiinflammatory therapy with canakinumab for atherosclerotic disease. The New England Journal of Medicine, 377(12), 1119–1131.
Ridker, P. M., et al. (2019). Low-dose methotrexate for the prevention of atherosclerotic events. The New England Journal of Medicine, 380(8), 752–762.
Pan, W., et al. (2019). Immunomodulation by exosomes in myocardial infarction. Journal of Cardiovascular Translational Research, 12(1), 28–36.
Leung, Y. Y., Yao Hui, L. L., & Kraus, V. B. (2015). Colchicine—update on mechanisms of action and therapeutic uses. Seminars in Arthritis and Rheumatism, 45(3), 341–350.
Crittenden, D. B., et al. (2012). Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. The Journal of Rheumatology, 39(7), 1458–1464.
Langevitz, P., et al. (2001). Prevalence of ischemic heart disease in patients with familial Mediterranean fever. The Israel Medical Association Journal, 3(1), 9–12.
Nidorf, S. M., et al. (2013). Low-dose colchicine for secondary prevention of cardiovascular disease. Journal of the American College of Cardiology, 61(4), 404–410.
Nidorf, S. M., et al. (2019). The effect of low-dose colchicine in patients with stable coronary artery disease: the LoDoCo2 trial rationale, design, and baseline characteristics. American Heart Journal, 218, 46–56.
Deftereos, S., et al. (2013). Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. Journal of the American College of Cardiology, 61(16), 1679–1685.
Tardif, J. C., et al. (2019). Efficacy and safety of low-dose colchicine after myocardial infarction. The New England Journal of Medicine, 381(26), 2497–2505.
Bhattacharyya, B., et al. (2008). Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Medicinal Research Reviews, 28(1), 155–183.
Ganguly, A., et al. (2013). Microtubule dynamics control tail retraction in migrating vascular endothelial cells. Molecular Cancer Therapeutics, 12(12), 2837–2846.
Paschke, S., et al. (2013). Technical advance: inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments. Journal of Leukocyte Biology, 94(5), 1091–1096.
Peachman, K. K., et al. (2004). Functional microtubules are required for antigen processing by macrophages and dendritic cells. Immunology Letters, 95(1), 13–24.
Sullivan, D. P., & Muller, W. A. (2014). Neutrophil and monocyte recruitment by PECAM, CD99, and other molecules via the LBRC. Seminars in Immunopathology, 36(2), 193–209.
Martinon, F., et al. (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 440(7081), 237–241.
Pope, R. M., & Tschopp, J. (2007). The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis and Rheumatism, 56(10), 3183–3188.
Cimmino, G., et al. (2018). Colchicine reduces platelet aggregation by modulating cytoskeleton rearrangement via inhibition of cofilin and LIM domain kinase 1. Vascular Pharmacology, 111, 62–70.
Phinikaridou, A., et al. (2009). A robust rabbit model of human atherosclerosis and atherothrombosis. Journal of Lipid Research, 50(5), 787–797.
Phinikaridou, A., et al. (2010). In vivo detection of vulnerable atherosclerotic plaque by MRI in a rabbit model. Circulation. Cardiovascular Imaging, 3(3), 323–332.
Schroeder, S., et al. (2001). Noninvasive detection and evaluation of atherosclerotic coronary plaques with multislice computed tomography. Journal of the American College of Cardiology, 37(5), 1430–1435.
Yla-Herttuala, S., et al. (2013). Stabilization of atherosclerotic plaques: an update. European Heart Journal, 34(42), 3251–3258.
Stone, G. W., et al. (2011). A prospective natural-history study of coronary atherosclerosis. The New England Journal of Medicine, 364(3), 226–235.
Naghavi, M., et al. (2003). From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation, 108(15), 1772–1778.
Arbab-Zadeh, A., & Fuster, V. (2015). The myth of the “vulnerable plaque”: transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment. Journal of the American College of Cardiology, 65(8), 846–855.
Chiu, B., et al. (2011). Fast plaque burden assessment of the femoral artery using 3D black-blood MRI and automated segmentation. Medical Physics, 38(10), 5370–5384.
Kantor, B., et al. (2009). Coronary computed tomography and magnetic resonance imaging. Current Problems in Cardiology, 34(4), 145–217.
Vaidya, K., et al. (2018). Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study. JACC: Cardiovascular Imaging, 11(2 Pt 2), 305–316.
Bauriedel, G., et al. (1994). Colchicine antagonizes the activity of human smooth muscle cells cultivated from arteriosclerotic lesions after atherectomy. Coronary Artery Disease, 5(6), 531–539.
Tatsumi, M., et al. (2003). Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. Radiology, 229(3), 831–837.
Tawakol, A., et al. (2005). Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. Journal of Nuclear Cardiology, 12(3), 294–301.
Ishii, H., et al. (2010). Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention. Clinical Therapeutics, 32(14), 2337–2347.
Vucic, E., et al. (2011). Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. JACC: Cardiovascular Imaging, 4(10), 1100–1109.
Martinez, G. J., Celermajer, D. S., & Patel, S. (2018). The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis, 269, 262–271.
Martinez, G. J., et al. (2015). Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. Journal of the American Heart Association, 4(8), e002128.
Yabushita, H., et al. (2002). Characterization of human atherosclerosis by optical coherence tomography. Circulation, 106(13), 1640–1645.
Rodriguez-Granillo, G. A., et al. (2005). New insights towards catheter-based identification of vulnerable plaque. Revista Española de Cardiología, 58(10), 1197–1206.
Puri, R., et al. (2015). Impact of statins on serial coronary calcification during atheroma progression and regression. Journal of the American College of Cardiology, 65(13), 1273–1282.
Kaminiotis, V. V., et al. (2017). Per os colchicine administration in cholesterol fed rabbits: triglycerides lowering effects without affecting atherosclerosis progress. Lipids in Health and Disease, 16(1), 184.
Wojcicki, J., et al. (1986). The effect of colchicine on the development of experimental atherosclerosis in rabbits. Polish Journal of Pharmacology and Pharmacy, 38(4), 343–348.
Brooks, P. M., Burton, D., & Forrest, M. J. (1987). Crystal-induced inflammation in the rat subcutaneous air-pouch. British Journal of Pharmacology, 90(2), 413–419.
Maduri, S., & Atla, V. R. (2012). Formulation of colchicine ointment for the treatment of acute gout. Singapore Medical Journal, 53(11), 750–754.
Marcovici, I., et al. (1993). Colchicine and post-inflammatory adhesions in a rabbit model: a dose-response study. Obstetrics and Gynecology, 82(2), 216–218.
Angelidis, C., et al. (2018). Colchicine pharmacokinetics and mechanism of action. Current Pharmaceutical Design, 24(6), 659–663.
This work was supported by a grant from the Sociedad Española de Cardiología, a grant from the Instituto de Salud Carlos III of Spain and Fondo Europeo de Desarrollo Regional (FEDER, “Una manera de hacer Europa”) (FIS-FEDER PI14-01427 to J. Mateo) and a grant from Fundación BBVA to J. Ruiz-Cabello. The CNIC is supported by the Instituto de Salud Carlos III, the Ministry of Science and Innovation and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). CIC biomaGUNE is supported by the Spanish State Research Agency of MICIN under the María de Maeztu Units of Excellence Program from MDM-2017-0720.
This article does not contain any studies with human participants performed by any of the authors. All institutional and national guidelines for the care and use of laboratory animals were followed and approved by the appropriate institutional committees.
Conflict of Interest
The authors declare that they have no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Associate Editor Paul J. R. Barton oversaw the review of this article
About this article
Cite this article
Cecconi, A., Vilchez-Tschischke, J.P., Mateo, J. et al. Effects of Colchicine on Atherosclerotic Plaque Stabilization: a Multimodality Imaging Study in an Animal Model. J. of Cardiovasc. Trans. Res. 14, 150–160 (2021). https://doi.org/10.1007/s12265-020-09974-7
- Animal model
- Plaque morphology